Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including ...

Fintel reports that on May 28, 2025, Leerink Partners downgraded their outlook for Rocket Pharmaceuticals (NasdaqGM:RCKT) ...

Fintel reports that on May 27, 2025, Needham downgraded their outlook for Rocket Pharmaceuticals (NasdaqGM:RCKT) from Buy to ...

Sami Corwin, an analyst at William Blair, maintained his Outperform rating on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) on ...

Zilliz, creator of the leading open-source vector database Milvus, today announced that Milvus has achieved 35,000 stars on GitHub, establishing it as the most popular vector database platform ...

FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...

Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to ...

BioMarin Pharmaceutical Inc., a biotechnology company ... an adeno associated virus vector for the treatment of severe hemophilia A. The company’s products under development include BMN 333 ...

The global Phenylketonuria (PKU) Treatment is undergoing a strategic transformation, driven by novel drug candidates and a more targeted understanding of unmet clinical needs. With a global prevalence ...

Dengue Vaccines Market Projected to Grow from USD 90 Million in 2025 to Nearly USD 200 Million by 2035The global Dengue Vaccines Market is expected to be reach USD 90.0 million in 2025 and is likely ...

The FDA has slapped a clinical hold on Rocket Pharmaceuticals’ pivotal gene therapy trial in response to a death. Rocket, ...

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.